-
-
-
-
-
-
-
Codexis (CDXS) Tops Q2 EPS by 3c
-
-
-
-
-
-
-
Codexis (CDXS) Misses Q4 EPS by 9c, Misses on Revenue; Offers FY25 Revenue Guidance
-
-
-
-
-
-
-
Codexis (CDXS) Licenses Genomics Life Science Enzyme Portfolio to Alphazyme
-
-
-
-
-
-
-
Form SC 13G/A CODEXIS, INC. Filed by: ARK Investment Management LLC
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

